^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Mucosal Melanoma

    Related cancers:
    7d
    Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma (clinicaltrials.gov)
    P2, N=19, Recruiting, Washington University School of Medicine | Trial completion date: Feb 2029 --> Jul 2032 | Trial primary completion date: Feb 2027 --> Jul 2030
    Trial completion date • Trial primary completion date
    |
    Keytruda (pembrolizumab)
    7d
    Rac1 signaling-associated genes are upregulated in nodal metastasis of canine oral mucosal melanoma. (PubMed, Vet Pathol)
    Overall, the results of this investigation point to a significant role for Rac1 signaling in the pathogenesis of OMM metastasis to regional lymph nodes. The Rac1 signaling-associated genes highlighted herein are indeed involved in the activation of cellular migration, and one, or more, may represent a future therapeutic target to prevent metastatic dissemination, or treat OMM with distant metastases.
    Journal
    |
    NODAL (Nodal Growth Differentiation Factor)
    8d
    Pathway-Specific Therapeutic Modulation of Melanoma: Small-Molecule Inhibition of BRAF-MEK and KIT Signaling in Contemporary Precision Oncology with a Special Focus on Vemurafenib, Trametinib, and Imatinib. (PubMed, J Clin Med)
    Despite substantial advances, secondary mutations and reactivation of oncogenic signaling remain major challenges. This narrative review integrates data from clinical, preclinical, and real-world studies to update the current understanding of targeted therapies in cutaneous melanoma and highlight ongoing research aimed at overcoming resistance and optimizing personalized treatment strategies.
    Review • Journal
    |
    BRAF (B-raf proto-oncogene) • KIT (KIT proto-oncogene, receptor tyrosine kinase)
    |
    BRAF V600E
    |
    Mekinist (trametinib) • Zelboraf (vemurafenib) • imatinib
    8d
    KEYNOTE-B77: BO-112 With Pembrolizumab in Unresectable Malignant Melanoma (clinicaltrials.gov)
    P2, N=42, Completed, Highlight Therapeutics | Active, not recruiting --> Completed
    Trial completion
    |
    BRAF (B-raf proto-oncogene) • CD4 (CD4 Molecule)
    |
    Keytruda (pembrolizumab) • polyinosinic:polycytidylic acid (BO-112)
    9d
    Comparative Insights into Cutaneous, Mucosal, and Vulvovaginal Melanomas: Biology, Targeted Therapies, and Survival with a Focus on Immune Checkpoint Inhibitors. (PubMed, J Pers Med)
    Mucosal and vulvovaginal melanomas are biologically and clinically distinct from cutaneous melanoma and continue to have poor survival outcomes. Their rarity restricts high-quality evidence, highlighting the need for collaborative, innovative research to inform effective treatment strategies.
    Review • Journal • Checkpoint inhibition • Tumor mutational burden • IO biomarker
    |
    BRAF (B-raf proto-oncogene) • TMB (Tumor Mutational Burden) • NRAS (Neuroblastoma RAS viral oncogene homolog)
    |
    TMB-H • BRAF mutation • NRAS mutation • TMB-L
    13d
    APX005M in Combination With Systemic Pembrolizumab in Patients With Metastatic Melanoma (clinicaltrials.gov)
    P1/2, N=34, Terminated, M.D. Anderson Cancer Center | Active, not recruiting --> Terminated; <75% participant accrual
    Trial termination
    |
    Keytruda (pembrolizumab) • sotigalimab (PYX-107)
    15d
    Neo IRENIE (NEOadjuvant Ipilimumab, RElatlimab, NIvolumab Evaluation) (clinicaltrials.gov)
    P2, N=531, Not yet recruiting, Melanoma Institute Australia | N=297 --> 531 | Initiation date: Sep 2025 --> Dec 2025 | Trial primary completion date: Sep 2027 --> Dec 2027
    Enrollment change • Trial initiation date • Trial primary completion date • IO biomarker
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab) • relatlimab (BMS-986016)
    16d
    Combination of Carilizumab, Apatinib, and Radiotherapy for Advanced Mucosal Melanoma (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
    New P2 trial
    |
    AiRuiKa (camrelizumab) • AiTan (rivoceranib)
    17d
    A Study to Investigate the Antitumor Activity, Safety, Tolerability, and Pharmacokinetics of BGB-A445 in Combination With Tislelizumab in Participants With Select Advanced Solid Tumors. (clinicaltrials.gov)
    P1/2, N=113, Active, not recruiting, BeiGene | N=202 --> 113 | Trial primary completion date: Oct 2026 --> May 2025
    Enrollment change • Trial primary completion date
    |
    cisplatin • Tevimbra (tislelizumab-jsgr) • BGB-A445
    17d
    NEOREM-NEO-1: Neo-adjuvant Immunotherapy in Patients With Localized Melanoma (clinicaltrials.gov)
    P2, N=50, Not yet recruiting, UNICANCER
    New P2 trial
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab)
    18d
    SWOG S1801: A Study to Compare the Administration of Pembrolizumab After Surgery Versus Administration Both Before and After Surgery for High-Risk Melanoma (clinicaltrials.gov)
    P2, N=313, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Oct 2025 --> Oct 2026
    Trial completion date
    |
    CD4 (CD4 Molecule)
    |
    Keytruda (pembrolizumab)
    18d
    A novel germline NF1 splicing variant drives the onset of an anorectal mucosal melanoma in a patient with a stable and durable nivolumab response. (PubMed, Pathologica)
    The tGEP analysis unveiled a macrophagic infiltration, with a pro-inflammatory M1-type polarization, in the context of lack of PD-L1 expression. The response to nivolumab in a germline NF1-driven ARMM case seems independent from levels of TMB and PD-L1 expression and may be mediated by inflammatory response induced by M1-polarized macrophages.
    Journal • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden) • NF1 (Neurofibromin 1)
    |
    PD-L1 expression • TMB-L
    |
    Opdivo (nivolumab)